Pharmacokinetics of Anti-tuberculosis Drugs in Children

被引：0
作者：
Geetha Ramachandran
A. K. Hemanth Kumar
Soumya Swaminathan
机构：
[1] Tuberculosis Research Centre (Indian Council of Medical Research),
[2] UNICEF/UNDP/World Bank//WHO Special Programme for Research & Training in Tropical Diseases,undefined
来源：
The Indian Journal of Pediatrics | 2011年 / 78卷
关键词：
Pharmacokinetics; Children; TB;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tuberculosis (TB) is among the top 10 causes of death among children worldwide. Recent reports suggest that the currently recommended dosages of first-line anti-TB drugs are not adequate in children, particularly younger children. The objective of this review was to synthesize available pharmacokinetic data of anti-TB drugs in children from different settings that would help determine optimal doses of anti-TB drugs, in order to provide evidence-based recommendations. A PubMed database was searched from 1970 to present using the terms rifampicin, isoniazid, pyrazinamide, ethambutol, pharmacokinetics, HIV, TB, nutrition and children. References from identified articles were also reviewed and abstract from recent meetings were included. Available pharmacokinetic data from different settings suggest that age, nutritional status, HIV infection and gene polymorphisms in drug metabolising enzymes could significantly influence the pharmacokinetics of first-line anti-TB drugs. However, most of the pharmacokinetic studies conducted so far in children have failed to associate drug concentrations with treatment outcomes. Hence, more studies to examine the relationship between drug pharmacokinetics and response to anti-TB treatment are required. Studies to examine the impact of nutritional status and HIV infection on the pharmacokinetics of anti-TB drugs in children are needed.
引用
收藏
页码：435 / 442
页数：7
相关论文
共 136 条
[1]  
Schaaf HS(2005)Isoniazid pharmacokinetics in children treated for respiratory tuberculosis Arch Dis Child 90 614-8
[2]  
Parkin DP(2010)Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis Scand J Infect Dis 42 294-8
[3]  
Seifart HI(2009)Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines Clin Infect Dis 48 1547-53
[4]  
Thee S(2009)Rifampicin serum levels in childhood tuberculosis Int J Tuberc Lung Dis 13 1106-11
[5]  
Detjen A(2009)Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalised for the management of severe forms of tuberculosis BMC Med 7 19-29
[6]  
Wahn U(2006)Ethambutol dosage for the treatment of children: literature review and recommendations Int J Tuberc Lung Dis 10 1318-30
[7]  
Magdorf K(2006)Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection Antimicrob Agents Chemother 50 407-13
[8]  
Mcllleron H(2002)Antiretroviral pharmacokinetics in the pediatric population—A review Clin Pharmacokinet 41 1115-33
[9]  
Willemse M(2002)Treatment of childhood tuberculosis with a 6 month directly observed regimen of only 2 weeks of daily therapy Pediatr Infect Dis J 21 91-7
[10]  
Werely CJ(2000)Treatment of tuberculosis Indian J Pediatr 67 S14-20
12345678910